View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. Deals Analysis
August 4, 2022

Europe’s medical devices industry saw a rise of 8.57% in cross border deal activity in Q2 2022

By Carmen

Led by $1bn acquisition of MediFox DAN Group, Europe’s medical devices industry saw a rise of 8.57% in cross border deal activity during Q2 2022, when compared to the last four-quarter average, according to GlobalData’s deals database.

  • Embed this chart

    Embed this chart into your website

    Copy and paste the image source into your website to display the chart.


A total of 76 cross border deals worth $3.5bn were announced for the region during Q2 2022, against the last four-quarter average of 70.00 deals.

Of all the deal types, M&A saw most activity in Q2 2022 with 36 deals, representing a 47.4% share for the region.

In second place was venture financing with 31 deals, followed by private equity deals with nine transactions, respectively capturing a 40.8% and 11.8% share of the overall cross border deal activity for the quarter.

In terms of value of cross border deals, M&A was the leading category in Europe’s medical devices industry with $2.16bn, while private equity and venture financing deals totalled $874.2m and $464.06m, respectively.

Europe medical devices industry cross border deals in Q2 2022: Top deals

The top five medical devices cross border deals accounted for a 74.9% share of the overall value during Q2 2022.

The combined value of the top five cross border deals stood at $2.62bn, against the overall value of $3.5bn recorded for the quarter.

1) ResMed $1bn acquisition deal with MediFox DAN Group

2) The $797.86m private equity of SPT Labtech by EQT IX Fund

3) Wallaby Medical $541.63m acquisition deal with Phenox

4) The $141.73m acquisition of Aran Biomedical by Integer

5) Straumann $138.06m acquisition deal with SunshineSmile

Related Companies

Verdict deals analysis methodology

This analysis considers only announced and completed cross border deals from the GlobalData financial deals database and excludes all terminated and rumoured deals. Country and industry are defined according to the headquarters and dominant industry of the target firm. The term ‘acquisition’ refers to both completed deals and those in the bidding stage.

GlobalData tracks real-time data concerning all merger and acquisition, private equity/venture capital and asset transaction activity around the world from thousands of company websites and other reliable sources.

More in-depth reports and analysis on all reported deals are available for subscribers to GlobalData’s deals database.

Topics in this article: ,
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy


Thank you for subscribing to Medical Device Network